Genetix Biotherapeutics, formerly known as bluebird bio, is dedicated to transforming the lives of patients with rare genetic diseases through pioneering genetic therapies. The rebranding reflects a renewed commitment to core values and the mission of providing innovative treatments for conditions such as sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy (CALD).

With cutting-edge, one-time therapies, Genetix aims to address the underlying causes of these diseases, offering potential cures rather than mere symptom management. Their therapies utilize patients' own blood stem cells, modified to incorporate functioning copies of the affected genes, significantly improving patient outcomes and quality of life.

The company's leadership, armed with extensive experience in biotechnology and commercial strategy, is focused on enhancing patient access and treatment experiences. Genetix Biotherapeutics also emphasizes long-term safety through ongoing clinical trials and a robust patient support program, ensuring families receive the guidance they need throughout the treatment journey.